EP1282411A4 - Methode de traitement anticancereux - Google Patents
Methode de traitement anticancereuxInfo
- Publication number
- EP1282411A4 EP1282411A4 EP01927380A EP01927380A EP1282411A4 EP 1282411 A4 EP1282411 A4 EP 1282411A4 EP 01927380 A EP01927380 A EP 01927380A EP 01927380 A EP01927380 A EP 01927380A EP 1282411 A4 EP1282411 A4 EP 1282411A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20002800P | 2000-04-26 | 2000-04-26 | |
US200028P | 2000-04-26 | ||
PCT/US2001/040237 WO2001080849A1 (fr) | 2000-04-26 | 2001-03-02 | Methode de traitement anticancereux |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1282411A1 EP1282411A1 (fr) | 2003-02-12 |
EP1282411A4 true EP1282411A4 (fr) | 2008-05-21 |
Family
ID=22740013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01927380A Withdrawn EP1282411A4 (fr) | 2000-04-26 | 2001-03-02 | Methode de traitement anticancereux |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1282411A4 (fr) |
AU (1) | AU2001253836A1 (fr) |
WO (1) | WO2001080849A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10160796A1 (de) * | 2001-12-11 | 2003-06-26 | Wulf Droege | Verwendung einer Cystein-haltigen Substanz zur Steigerung der Atmungsaktivität und Erythropoetin-Produktion |
AU2003294668A1 (en) * | 2002-09-06 | 2004-04-08 | Institut Curie | Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas |
DE10337638A1 (de) * | 2003-08-16 | 2005-03-24 | Kirschfeld, Kuno, Prof. Dr. | Verfahren zur Behandlung der Prostatitis |
US20060019907A1 (en) * | 2004-07-12 | 2006-01-26 | Research Development Foundation | Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof |
WO2011091807A1 (fr) * | 2010-01-31 | 2011-08-04 | Abdelrahman Shata Mohammed Shata | Anticoagulant et glutathion pour le traitement du cancer |
WO2011135784A1 (fr) | 2010-04-28 | 2011-11-03 | 株式会社Ihi | Médicament traitant les tumeurs cérébrales |
JP5873656B2 (ja) | 2011-06-13 | 2016-03-01 | 株式会社Ihi | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
WO2016046989A1 (fr) * | 2014-09-26 | 2016-03-31 | 株式会社Ihi | Agent anticancéreux et procédé de destruction de cellules cancéreuses |
JP2017128552A (ja) * | 2016-01-22 | 2017-07-27 | 株式会社Ihi | 抗癌剤、抗癌剤の制御方法 |
CN112121043A (zh) * | 2020-10-27 | 2020-12-25 | 澳门大学 | 双香豆素在抗肿瘤中的应用 |
CN114558122B (zh) * | 2022-04-27 | 2023-02-21 | 北京肿瘤医院(北京大学肿瘤医院) | 放射核素标记的过氧化氢酶及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334382A (en) * | 1993-02-25 | 1994-08-02 | Sterling Winthrop Inc. | Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions |
US5756091A (en) * | 1993-04-22 | 1998-05-26 | Cellfire Incorporated | Method of treating tumour cells using catalase |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824664A (en) * | 1993-03-26 | 1998-10-20 | U.S. Bioscience, Inc. | Suppression of HIV expression by organic thiophosphate |
US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
-
2001
- 2001-03-02 WO PCT/US2001/040237 patent/WO2001080849A1/fr active Search and Examination
- 2001-03-02 AU AU2001253836A patent/AU2001253836A1/en not_active Abandoned
- 2001-03-02 EP EP01927380A patent/EP1282411A4/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334382A (en) * | 1993-02-25 | 1994-08-02 | Sterling Winthrop Inc. | Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions |
US5756091A (en) * | 1993-04-22 | 1998-05-26 | Cellfire Incorporated | Method of treating tumour cells using catalase |
Non-Patent Citations (4)
Title |
---|
BRAR SUKHDEV S ET AL: "Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 280, no. 3 Part 1, March 2001 (2001-03-01), pages C659 - C676, XP002475662, ISSN: 0002-9513 * |
LIU TSAN-ZON ET AL: "Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines", CANCER LETTERS, vol. 151, no. 1, 3 April 2000 (2000-04-03), pages 49 - 56, XP002475661, ISSN: 0304-3835 * |
SCHWARTZ S A ET AL: "The role of NF-[kappa]B/I[kappa]B proteins in cancer: Implications for novel treatment strategies", SURGICAL ONCOLOGY 1999 GB, vol. 8, no. 3, 1999, pages 143 - 153, XP002475660, ISSN: 0960-7404 * |
See also references of WO0180849A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001080849A1 (fr) | 2001-11-01 |
EP1282411A1 (fr) | 2003-02-12 |
AU2001253836A1 (en) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0014969D0 (en) | Novel method of treatment | |
AU2003226301A8 (en) | Method of treating cancer | |
IL213240A0 (en) | Method of treatment using lighnd-immunogen conjugates | |
AU2003256847A8 (en) | Method of treating cancer | |
EP1393708A4 (fr) | Procede de traitement des cheveux | |
SI1176964T1 (sl) | Uporaba et743 za zdravljenje raka | |
EP1320376A4 (fr) | Traitement du cancer de la prostate | |
EP1282411A4 (fr) | Methode de traitement anticancereux | |
GB2389532C (en) | The method of treating cancer | |
EP1401377A4 (fr) | Methodes de traitement du cancer | |
AU2001241779A1 (en) | Method of treatment of prostate cancer | |
AU9402401A (en) | Treatment of cancers | |
EP1553965A4 (fr) | Methode de traitement des tumeurs | |
GB0008921D0 (en) | Method of treatment | |
HK1046853A1 (zh) | 治療肝癌的方法及組成物 | |
GB0118883D0 (en) | Method for treating objects | |
GB0026838D0 (en) | Treatment method | |
EP1423118A4 (fr) | Procede et preparation de traitement du cancer | |
GB0026015D0 (en) | Cancer treatment | |
GB0122810D0 (en) | Method for treating objects | |
GB0123897D0 (en) | Method for treating objects | |
IL161630A0 (en) | Methods of treating endometreosis | |
EP1303281A4 (fr) | Methodes de traitement | |
GB0021481D0 (en) | Method of treating fabric | |
AU2002360454A8 (en) | Methods and compositions for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021122 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080423 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20080414BHEP Ipc: A61K 45/06 20060101ALI20080414BHEP Ipc: A61K 31/44 20060101ALI20080414BHEP Ipc: A61K 31/66 20060101ALI20080414BHEP Ipc: A61K 31/452 20060101ALI20080414BHEP Ipc: A61K 31/41 20060101ALI20080414BHEP Ipc: A61K 31/37 20060101ALI20080414BHEP Ipc: A61K 31/366 20060101ALI20080414BHEP Ipc: A61K 31/28 20060101ALI20080414BHEP Ipc: A61K 31/221 20060101ALI20080414BHEP Ipc: A61K 31/198 20060101ALI20080414BHEP Ipc: A61K 31/122 20060101ALI20080414BHEP Ipc: A61K 31/05 20060101AFI20011106BHEP |
|
17Q | First examination report despatched |
Effective date: 20080724 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090204 |